Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text] December 1, 2008 LA JOLLA, Calif.–(BUSINESS WIRE)–Novelix Pharmaceuticals, Inc. (Novelix), a biopharmaceutical company developing small molecule cancer therapeutics, announced today that it has selected the large-market indication of actinic keratosis (AK) as the main focus of the company’s dermatology development program. NVX-207, a targeted therapeutic regulating caspase-9, […]